Denali Therapeutics (DNLI) Debt Ratio (2022)

Denali Therapeutics (DNLI) posted quarterly Debt Ratio of 0.0 for Q4 2022, up 155.64% quarter-over-quarter from 0.0 in Q3 2022.

Denali Therapeutics (DNLI) Debt Ratio (2022) Analysis & Trends

Denali Therapeutics (DNLI) has reported Debt Ratio for 1 consecutive years, with 0.0 the latest figure, recorded in Q4 2022.

In Q4 2022, Debt Ratio changed N/A year-over-year to 0.0; the TTM figure through Dec 2022 stood at 0.0 (changed N/A YoY), while the FY2022 annual figure was 0.0, changed N/A from the prior year.
Debt Ratio advanced to 0.0 in Q4 2022 per DNLI's latest filing, from 0.0 in the prior quarter.
Across five years, Debt Ratio topped out at 0.0 in Q4 2022 and bottomed at 0.0 in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	Denali Therapeutics	3.90 Bn	3.90 Bn	3.51 Mn	-

Download Data